Allele-agnostic KCNH1 suppression rescues gain-of-function developmental epileptic encephalopathy
- 1Northwestern University Feinberg School of Medicine
Abstract
Gain-of-function variants in KCNH1, which encodes the voltage-gated potassium channel Kv10.1, cause developmental and epileptic encephalopathies (DEEs) characterized by seizures, developmental delay and intellectual disability. While pathogenic variants enhance channel activity, loss of KCNH1 is tolerated in humans and mice, suggesting that allele-agnostic gene suppression may represent a viable therapeutic strategy. Here, we developed a gapmer antisense oligonucleotide (ASO) targeting KCNH1 and evaluated its efficacy in human induced pluripotent stem cell (iPSC)-derived neurons and a knock-in mouse model of KCNH1-related disorder. Neurons carrying the pathogenic KCNH1 variants I494V or G375R exhibited a shared phenotype characterized by hyperpolarized resting membrane potential and abnormalities in neuronal network activity despite largely preserved intrinsic firing properties. ASOs efficiently reduced KCNH1 expression without disrupting network activity in control neurons. In contrast, ASO treatment normalized network dysfunction across both mutant genotypes, demonstrating that distinct KCNH1 gain-of-function variants converge on a reversible disease state. To assess the efficacy of ASOs in vivo, we generated a new Kcnh1-R357Q knock-in mouse model that exhibited profound seizures and early mortality. A single ASO treatment reduced seizure burden significantly and restored survival to near-normal levels. Together, these findings establish KCNH1 suppression as a precision therapeutic strategy for KCNH1-related DEEs and provide a framework for treating gain-of-function epilepsies in which partial gene reduction is clinically tolerated.
Related
- Elevated neuronal excitability and seizure susceptibility in a mouse model of SCN2A-related developmental and epileptic encephalopathy
- Molecular characterization and pathogenicity stratification of YWHAG missense variants in developmental and epileptic encephalopathy.
- Expanded molecular pathomechanisms of GlyR α2 subunit variants in neurodevelopmental disorders and epileptic encephalopathy
- Clinic-to-Mechanism: Unraveling in-depth molecular dysfunctions caused by a GluN2B C-Terminal deletion in developmental and epileptic encephalopathies
- Nano-Zinc Iron Oxide Elicits Oxidative Stress-Driven Midgut Damage and Developmental Suppression in Bombyx mori.
BibTeX
@misc{chi2026alleleagnostic,
title = {{Allele-agnostic KCNH1 suppression rescues gain-of-function developmental epileptic encephalopathy}},
author = {W. Chi and E. E. Corbett and C. H. Thompson and D. Simkin and H. Adil and N. A. Hawkins and N. A. Callow and L. Barse and A. L. George and J. A. Kearney and E. Kiskinis},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.06.764929},
url = {https://www.biorxiv.org/content/10.64898/2026.11.06.764929v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Allele-agnostic KCNH1 suppression rescues gain-of-function developmental epileptic encephalopathy
AU - W. Chi
AU - E. E. Corbett
AU - C. H. Thompson
AU - D. Simkin
AU - H. Adil
AU - N. A. Hawkins
AU - N. A. Callow
AU - L. Barse
AU - A. L. George
AU - J. A. Kearney
AU - E. Kiskinis
PY - 2026
DA - 2026/11/06
PB - bioRxiv
DO - 10.64898/2026.11.06.764929
UR - https://www.biorxiv.org/content/10.64898/2026.11.06.764929v1
AB - Gain-of-function variants in KCNH1, which encodes the voltage-gated potassium channel Kv10.1, cause developmental and epileptic encephalopathies (DEEs) characterized by seizures, developmental delay and intellectual disability. While pathogenic variants enhance channel activity, loss of KCNH1 is tolerated in humans and mice, suggesting that allele-agnostic gene suppression may represent a viable therapeutic strategy. Here, we developed a gapmer antisense oligonucleotide (ASO) targeting KCNH1 and evaluated its efficacy in human induced pluripotent stem cell (iPSC)-derived neurons and a knock-in mouse model of KCNH1-related disorder. Neurons carrying the pathogenic KCNH1 variants I494V or G375R exhibited a shared phenotype characterized by hyperpolarized resting membrane potential and abnormalities in neuronal network activity despite largely preserved intrinsic firing properties. ASOs efficiently reduced KCNH1 expression without disrupting network activity in control neurons. In contrast, ASO treatment normalized network dysfunction across both mutant genotypes, demonstrating that distinct KCNH1 gain-of-function variants converge on a reversible disease state. To assess the efficacy of ASOs in vivo, we generated a new Kcnh1-R357Q knock-in mouse model that exhibited profound seizures and early mortality. A single ASO treatment reduced seizure burden significantly and restored survival to near-normal levels. Together, these findings establish KCNH1 suppression as a precision therapeutic strategy for KCNH1-related DEEs and provide a framework for treating gain-of-function epilepsies in which partial gene reduction is clinically tolerated.
ER -